Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

The New England Journal of Medicine
Chloe OrkinWilliam R Spreen

Abstract

Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. We conducted a phase 3, randomized, open-label trial in which adults with HIV-1 infection who had not previously received antiretroviral therapy were given 20 weeks of daily oral induction therapy with dolutegravir-abacavir-lamivudine. Participants who had an HIV-1 RNA level of less than 50 copies per milliliter after 16 weeks were randomly assigned (1:1) to continue the current oral therapy or switch to oral cabotegravir plus rilpivirine for 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine. The primary end point was the percentage of participants who had an HIV-1 RNA level of 50 copies per milliliter or higher at week 48 (Food and Drug Administration snapshot algorithm). At week 48, an HIV-1 RNA level of 50 copies per milliliter or higher was found in 6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 (2.5%) who received oral therapy (adjusted difference, -0.4 percentage points; 95% confidence interval [CI], -2.8 to 2.1), a result that met the criterion for noninferiority for the primary end point (margin, 6 percentage points). An HIV-1 RNA l...Continue Reading

References

Jan 16, 2002·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·A Woodcock, C Bradley
Jun 3, 2006·The Journal of Infectious Diseases·Rochelle P WalenskyKenneth A Freedberg
Apr 7, 2011·AIDS and Behavior·Carmen OrtegoJavier Vejo
Oct 21, 2011·The New England Journal of Medicine·François-Xavier BlancUNKNOWN CAMELIA (ANRS 1295–CIPRA KH001) Study Team
Dec 4, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Sharon L KarmonMartin Markowitz
Nov 13, 2018·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Ethel D WeldAllison L Agwu
Dec 5, 2018·The Lancet Infectious Diseases·Joris HemelaarUNKNOWN WHO–UNAIDS Network for HIV Isolation Characterisation
Mar 5, 2020·The New England Journal of Medicine·Susan SwindellsWilliam R Spreen

❮ Previous
Next ❯

Citations

Apr 29, 2020·Nature Materials·Tanmay A KulkarniHoward E Gendelman
Jul 25, 2020·Nature Materials·Vicente SorianoCarmen de Mendoza
Sep 13, 2020·Current HIV/AIDS Reports·Elisa H Ignatius, Susan Swindells
Aug 30, 2020·Drugs·Kimberly K ScarsiCourtney V Fletcher
Mar 5, 2020·The New England Journal of Medicine·Susan SwindellsWilliam R Spreen
Aug 5, 2020·The Journal of Antimicrobial Chemotherapy·Giovanni GuaraldiCristina Mussini
Jun 17, 2020·Expert Review of Clinical Pharmacology·Andrea GiacomelliStefano Rusconi
Jun 26, 2020·MMW Fortschritte der Medizin·Elke Oberhofer
Aug 21, 2020·Proceedings of the National Academy of Sciences of the United States of America·Yoshiaki NishimuraMichael S Kay
Aug 24, 2020·New Directions for Child and Adolescent Development·Geoffrey Peter Garnett
Sep 15, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S SpringI Woolley
Dec 19, 2020·Current Opinion in Infectious Diseases·John Thornhill, Chloe Orkin
Nov 12, 2020·Current Opinion in Pharmacology·Yali SangFener Chen
Oct 14, 2020·Current Opinion in Pharmacology·Sean N AvedissianCourtney V Fletcher
Dec 4, 2020·The Lancet. HIV·Sharon R LewinUNKNOWN Sunnylands 2019 Working Group
Feb 6, 2021·Viruses·Marco BerrutiAntonio Di Biagio
Nov 3, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Giuliano RizzardiniDavid A Margolis
Feb 18, 2021·The Annals of Pharmacotherapy·Spencer H Durham, Elias B Chahine
Feb 13, 2021·Viruses·Steven J SmithStephen H Hughes
Feb 10, 2021·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jacob A PluznikAnne C Spaulding
Feb 25, 2021·Current Opinion in HIV and AIDS·John Thornhill, Chloe Orkin
Nov 10, 2020·International Journal of Antimicrobial Agents·Charles FlexnerSusan Swindells
Mar 5, 2020·The New England Journal of Medicine·Judith S Currier
Mar 5, 2021·Journal of Virus Eradication·Tristan J Barber, Laura J Waters
Oct 15, 2020·JAMA : the Journal of the American Medical Association·Michael S SaagPaul A Volberding
Dec 12, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Stephanie SpringIan Woolley
Mar 3, 2021·Antimicrobial Agents and Chemotherapy·Kirsten L WhiteAnita Niedziela-Majka
Apr 28, 2021·Journal of the International Association of Providers of AIDS Care·Kimberly K Scarsi, Susan Swindells
May 21, 2021·The Journal of Antimicrobial Chemotherapy·Charlotte CharpentierDiane Descamps

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.